Coherus Oncology
CHRS
183 hedge funds and large institutions have $975M invested in Coherus Oncology in 2022 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 59 increasing their positions, 72 reducing their positions, and 39 closing their positions.
1.65% less ownership
Funds ownership: 100.03% → 98.39% (-1.6%)
9% less funds holding
Funds holding: 201 → 183 (-18)
18% less repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 72
20% less capital invested
Capital invested by funds: $1.23B → $975M (-$251M)
46% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 39
98% less call options, than puts
Call options by funds: $11K | Put options by funds: $616K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$17.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.8M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$4.11M |
| 4 |
D.E. Shaw & Co
New York
|
+$3.44M |
| 5 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
+$2.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
-$19.5M |
| 2 |
RI
Redwood Investments
Boston,
Massachusetts
|
-$11.3M |
| 3 |
PA
Perceptive Advisors
New York
|
-$9.05M |
| 4 |
Swedbank
Stockholm,
Sweden
|
-$3.94M |
| 5 |
FAM
Fred Alger Management
New York
|
-$3.29M |
CHRS Hedge Fund Activity: Q1 2022 in Review
183 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q1 2022, worth a combined $975M — down 20% from $1.23B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of CHRS and 21 opened new positions — a net loss of 18 holders — while 72 trimmed existing stakes and 59 added.
The largest buyer was State Street, adding an estimated $17.1M. The largest seller was Suvretta Capital Management, exiting entirely with an estimated $19.5M sold.
- 183 institutional investors held Coherus Oncology (CHRS) as of Q1 2022, down from 201 in Q4 2021.
- Funds reported $975M of Coherus Oncology stock for Q1 2022, down 20% quarter-over-quarter.
- 21 funds opened new Coherus Oncology positions in Q1 2022 and 39 closed out, a net change of -18 holders.
- The largest Coherus Oncology buyer in Q1 2022 was State Street, an estimated $17.1M added.
- The largest Coherus Oncology seller in Q1 2022 was Suvretta Capital Management, an estimated $19.5M sold.
Based on aggregated 13F filings for Q1 2022.